Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1971 May;114(5):7-14.

One to two year treatment of Parkinson's disease with levodopa

One to two year treatment of Parkinson's disease with levodopa

L J Treciokas et al. Calif Med. 1971 May.

Abstract

One hundred patients with Parkinson's disease were treated with levodopa for more than a year at UCLA Medical Center. They were examined at given intervals and their improvement was graded. The optimum therapeutic dose was attained by balancing side effects against relief of symptoms and ranged from 1.5 grams to 8.0 grams per day (average 4.3 grams). There is no doubt that levodopa is the most effective treatment now available for Parkinson's disease. At the end of the first year, 60 percent of the patients improved 50 percent or better, and 10 percent were considered symptom-free. All major symptoms of this disease, including rigidity, akinesia and tremor, improved in variable degree. There were no serious abnormalities in the routine clinical laboratory tests. The comon side effects included nausea, vomiting and choreoathetoid dyskinesias. The side effects were not life threatening, but occasionally were major therapeutic challenges. Maximal benefits with minimal side effects were achieved only by careful adjustments of the levodopa dosage as the months went by. This needed careful management by the physician and cooperation by the patient. Anticholinergic medications or amantadine hydrochloride, sometimes both, usually supplemented the effect of the levodopa.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Trans Am Neurol Assoc. 1968;93:56-63 - PubMed
    1. Science. 1970 Jul 24;169(3943):395-7 - PubMed
    1. Pharmacol Rev. 1959 Jun;11(2, Part 2):490-3 - PubMed
    1. Wien Klin Wochenschr. 1961 Nov 10;73:787-8 - PubMed
    1. Neurology. 1970 Apr;20(4):377 - PubMed

Substances

LinkOut - more resources